EMA Seeks To Clarify Similarity Assessment
The European Medicines Agency has updated its reflection paper on methodologies for comparative quality assessment. The paper clarifies expectations on the assessment of similarity for manufacturing changes and for generic and biosimilar development by introducing the concept of “similarity condition.”
You may also be interested in...
Sponsors of three drugs have withdrawn their EU marketing authorization applications in the middle of the assessment process, including one for a bladder cancer therapy that was recently turned down in the US.
Sponsors of several new medicines are set to learn if their products are on track for pan-EU approval. One product on the list is Pfizer/Lilly’s osteoarthritis drug, tanezumab, which recently ran into trouble in the US.
A new position paper outlines several factors that sponsors must consider when planning to undertake decentralized clinical trials in Switzerland to ensure compliance with national legal and ethics requirements.